Evidence map›Paper›PMID 36040804›Full record

ArticleJCI insight2022

Alternative exon usage in TRIM21 determines the antigenicity of Ro52/TRIM21 in systemic lupus erythematosus.

Eduardo Gomez-Bañuelos, M Javad Wahadat, Jessica Li, Merlin Paz, Brendan Antiochos, Alessandra Ida Celia, Victoria Andrade, Dylan P Ferris, Daniel W Goldman, Erika Darrah and 2 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Autoimmunity: the neoantigen hypothesis.Frontiers in immunology · 2024
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 3 countries.

Eduardo Gomez-BañuelosDivision of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
M Javad WahadatDepartment of Immunology and.
Jessica LiDivision of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Merlin PazDivision of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Brendan AntiochosDivision of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Alessandra Ida CeliaDivision of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Victoria AndradeDivision of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Dylan P FerrisDivision of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Daniel W GoldmanDivision of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Erika DarrahDivision of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Michelle PetriDivision of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Felipe AndradeDivision of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Johns Hopkins University · USErasmus MC · NL

Funding

Hopkins Lupus CohortR01AR069572 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI PETRI, MICHELLE A · 2016 to 2020
$3.4M
The role of complement citrullination in RA pathogenesisR01AR069569 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI ANDRADE, FELIPE · 2016 to 2020
$1.8M
Autoimmunity to LINE-1-encoded antigens in SLE pathogenesisR21AI147598 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ANDRADE, FELIPE · 2020 to 2021
$450k
NIAID NIH HHS R21 AI147598NIAMS NIH HHS R01 AR069569NIAMS NIH HHS R01 AR069572
6 · The paper itself

Abstract

The origin and mechanisms of autoantigen generation in systemic lupus erythematosus (SLE) are poorly understood. Here, we identified SLE neutrophils activated in vivo by IFN as a prominent source of Ro52, also known as tripartite motif-containing protein 21 (TRIM21), a critical autoantigen historically thought to be primarily generated by keratinocytes in SLE. Different from mononuclear cells and keratinocytes, SLE neutrophils are enriched in several unique Ro52 species containing a core sequence encoded by exon 4 (Ro52Ex4) in TRIM21. Ro52Ex4 is the main target of anti-Ro52 antibodies and is found in 2 Ro52 variants (Ro52α and a potentially novel isoform termed Ro52γ) upregulated in SLE neutrophils. Further analysis of Ro52γ revealed a subset of autoantibodies against a unique C-terminal domain (Ro52γCT) generated from a frameshift due to the lack of exon 6 in Ro52γ. Antibodies to Ro52Ex4 and Ro52γCT distinguish SLE patient subsets characterized by distinct clinical, laboratory, treatment, and transcriptional profiles that are not discerned by the "classical" anti-Ro52 antibodies. These studies uncover IFN-activated neutrophils as a key source of unique immunogenic forms of Ro52 in SLE. Moreover, the finding of Ro52Ex4 and Ro52γCT as core targets of anti-Ro52 antibodies focus interest on Ro52γ as the potential isoform toward which immunological tolerance is initially lost in SLE.

Indexed as

Lupus Erythematosus, SystemicAutoantibodiesAutoantigensExonsHumansKeratinocytesAutoantibodiesAutoantigensAutoimmune diseasesAutoimmunityLupusNeutrophils

Identifiers

PMID36040804
PMCPMC9675474
OpenAlexW4293581890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.